Breaking News Instant updates and real-time market news.

RT

Taken private

$1.99

(0.00%)

, ARMK

Aramark

$42.33

(0.00%)

09:23
10/16/17
10/16
09:23
10/16/17
09:23

On The Fly: Pre-market Movers

HIGHER: Ruby Tuesday (RT), up 19.1% after announcing it will be acquired by NRD Capital for $2.40 per share... Aramark (ARMK), up 4% after announcing it will acquire Avendra for $1.35B and AmeriPride Services for $1B... Shire (SHPG), up 2.3% after its new formulation of Oncaspar received a positive opinion from the Committee for Medicinal Products for Human Use... Apple (AAPL), up just under 1% after being upgraded to Overweight from Sector Weight at KeyBanc... Health Insurance Innovations (HIIQ), up 11.9% after reporting preliminary third quarter results... Concurrent (CCUR), up 16.4% after it agrees to sell its Content Delivery & Storage Business to Vecima Networks for $29M. LOWER: Charles Schwab (SCHW), down 1.6% after reporting quarterly results... Concordia (CXRX), down 4.4% after announcing it will defer payment of approximately $26M of interest due on its $735M unsecured notes... ITUS (ITUS), down 11% after filing a $24M mixed securities shelf.

RT

Taken private

$1.99

(0.00%)

ARMK

Aramark

$42.33

(0.00%)

SHPG

Shire

$154.07

1.79 (1.18%)

AAPL

Apple

$156.99

0.99 (0.63%)

HIIQ

Health Insurance Innovations

$18.90

0.8 (4.42%)

CCUR

CCUR Holdings

$5.80

-0.03 (-0.51%)

SCHW

Charles Schwab

$44.73

(0.00%)

CXRX

Concordia

$1.14

-0.02 (-1.72%)

ITUS

ITUS

$3.19

-0.22 (-6.45%)

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

  • 06

    Nov

  • 16

    Nov

  • 20

    Dec

RT Taken private
$1.99

(0.00%)

ARMK Aramark
$42.33

(0.00%)

01/10/17
LEHM
01/10/17
DOWNGRADE
Target $37
LEHM
Equal Weight
Aramark downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Manav Patnaik downgraded Aramark to Equal Weight saying the company's margin progress seems to be priced in at current valuation levels. The analyst lowered his price target for the shares to $37 from $38.
02/22/17
DBAB
02/22/17
INITIATION
Target $42
DBAB
Buy
Aramark initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Kevin McVeigh started Aramark with a Buy rating and $42 price target. The analyst expects margin expansion, end market reacceleration and easier comparisons in the second half of the year to drive the stock higher.
03/02/17
GSCO
03/02/17
UPGRADE
Target $44
GSCO
Conviction Buy
Aramark upgraded to Conviction Buy from Buy at Goldman
Goldman Sachs analyst Stephen Grambling upgraded Aramark to Conviction Buy from Buy saying the stock has further room to run as sales accelerate through the year on recent contract wins. The analyst views Aramark as a margin expansion story and keeps a $44 price target for the shares.
03/13/17
RBCM
03/13/17
DOWNGRADE
RBCM
Outperform
Aramark downgraded to Outperform from Top Pick at RBC Capital
RBC Capital analyst Gary Bisbee continues to believe that Aramark (ARMK) is "compelling," as he expects its revenue growth to accelerate in 2H17 and beat expectations. However, the analyst says that Gartner (IT) is now his most compelling mid-large cap idea over the next two to three years. He upgraded Gartner to Top Pick from Outperform today. Target on Aramark remains $42.
SHPG Shire
$154.07

1.79 (1.18%)

08/22/17
JEFF
08/22/17
NO CHANGE
JEFF
Buy
Shire CFO departure timing 'inopportune,' says Jefferies
Jefferies analyst David Steinberg called the "surprising move" of Shire CFO Jeff Poulton out of his current post and into a role at an agriculture biotech start-up "naturally raises some concerns" given the recent departure of the company's head of R&D, adding that the timing is "highly inopportune." However, after speaking with Poulton, the analyst's take is that the move is motivated by an interest in a more entrepreneurial opportunity. Steinberg keeps a Buy rating on Shire shares, which slid 3% yesterday.
07/14/17
CANT
07/14/17
NO CHANGE
CANT
Worries about Shire hemophilia franchise overdone, says Cantor
After speaking with a pediatric hematology/oncology physician, Cantor analyst Louise Chen reports that the doctor said that uptake of Roche's (RHHBY) hemophilia treatment, ACE910, "will be gradual" because of safety concerns. The analyst says that worries about Shire's (SHPG_) hemophilia franchise are overdone. She keeps a $222 price target and an Overweight rating on the stock.
08/16/17
EVER
08/16/17
INITIATION
Target $196
EVER
Outperform
Shire initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Shire with an Outperform and a $196 price target.
10/02/17
WELS
10/02/17
NO CHANGE
WELS
Outperform
Wells Fargo says Allergan discounting, rebating for Restasis typical of industry
Wells Fargo analyst David Maris noted that Shire (SHPG) filed an antitrust suit against Allergan (AGN) over its discounting and rebating for Restasis. However, what Shire claims is an anti-competitive scheme is no different from the normal course in the industry, said Maris. The analyst keeps an Outperform rating on Allergan shares.
AAPL Apple
$156.99

0.99 (0.63%)

10/13/17
LEHM
10/13/17
NO CHANGE
Target $161
LEHM
Equal Weight
Apple price target raised to $161 from $146 at Barclays
Barclays analyst Mark Moskowitz raised his price target for Apple to $161 while keeping an Equal Weight rating on the shares. Industry and media "noise" over supply chain constraints impacting iPhone AX volumes are likely to persist into the first half of 2018, Moskowitz tells investors in a research note titled "Bring in 'Da Noise, Bring Up 'Da Margin." This should ease by next year's June quarter, however, setting the stage for bigger year-over-year unit growth as well as higher gross margin trends, the analyst adds.
10/16/17
10/16/17
UPGRADE
Target $187

Overweight
Apple upgraded to Overweight from Sector Weight at Pacific Crest
Pacific Crest analyst Andy Hargreaves upgraded Apple to Overweight from Sector Weight with a price target of $187. The shares closed Friday up 99c to $156.99. Apple is in the early stages of a "more aggressive market segmentation strategy" that will likely increase its gross profit per user and drive gross margin higher, Hargreaves tells investors in a research note. The analyst, however, remains "somewhat pessimistic" on iPhone unit growth volumes. Increased gross margin assumptions rise his earnings per share estimate for fiscal year 2018 to $11.68 from $11.07. The analyst believes initial iPhone mix is likely to suggest strong high-end demand.
10/16/17
KEYB
10/16/17
NO CHANGE
KEYB
Apple supply chain to remain range-bound, says KeyBanc
KeyBanc analyst John Vinh says that because of supply constraints associated with the iPhone X, he anticipates Apple (AAPL) supply chain stocks will likely remain range-bound in the near term, given constraints make upside to estimates less likely, and constraints make it hard to assess true demand for the iPhone X. Additionally, his latest carrier survey indicates relatively lean iPhone 8 inventories despite muted demand and slightly higher demand for the iPhone 7. The analyst recommends investors continue to own Broadcom (AVGO), Cirrus Logic (CRUS), and Skyworks (SWKS).
10/16/17
KEYB
10/16/17
UPGRADE
KEYB
Overweight
Apple upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Andy Hargreaves upgraded Apple to Overweight from Sector Weight with a price target of $187. The shares closed Friday up 99c to $156.99. Apple is in the early stages of a "more aggressive market segmentation strategy" that will likely increase its gross profit per user and drive gross margin higher, Hargreaves tells investors in a research note. The analyst, however, remains "somewhat pessimistic" on iPhone unit growth volumes. Increased gross margin assumptions rise his earnings per share estimate for fiscal year 2018 to $11.68 from $11.07. The analyst believes initial iPhone mix is likely to suggest strong high-end demand. This report updates the firm to KeyBanc, which previously merged with Pacific Crest.
HIIQ Health Insurance Innovations
$18.90

0.8 (4.42%)

09/28/17
CHLM
09/28/17
NO CHANGE
CHLM
Buy
Health Insurance Innovations short report a misrepresentation, says Craig-Hallum
Craig-Hallum analyst George Sutton said the key issue at the heart of a new short report on Health Insurance Innovations is questioning the background of Stephen Dorfman, but the analyst does not believe he is the broker of record at the call center in question and thinks the report misrepsents how much of the company's revenue is generated by that center. The report also has the wrong person named as the company's head of compliance, the analyst noted.
09/12/17
CANT
09/12/17
NO CHANGE
Target $38
CANT
Overweight
Cantor not concerned by Health Insurance Innovations TPA license scenario
Cantor analyst Steven Halper said that Health Insurance Innovations issued a press release responding to a "misleading" short report posted on moxreports.com yesterday, noting that the Indiana Multi-State examination is ongoing and regulators have not yet provided any information regarding potential resolution, and that the author's claims of potential $100M in penalties were based on "unstated or inapplicable data points. The analyst adds that Health Insurance Innovations is working with the Florida Office of Insurance Regulation to reach a mutually agreeable resolution that would allow it to either "re-submit application or engage in discussions regarding whether the OIR will require the company to hold a third-party administrator license at all". While the analyst believes the TPA license scenario is unfortunate and not handled well by the company, Halper is not concerned about it as the company does not serve as a TPA. He reiterates an Overweight rating and $38 price target on the shares.
10/10/17
ADAM
10/10/17
NO CHANGE
Target $39
ADAM
Buy
Trump executive order positive for Health Insurance Innovations, says Canaccord
Canaccord analyst Richard Close noted the Wall Street Journal reported President Trump intends to sign an executive order to roll back certain insurance regulations, which could have a direct benefit to Health Insurance Innovations' business. The order would seek to reverse the Obama-era rule on short-term medical insurance, which limited the duration to no longer than three months, and revert it back to the previous duration of one-year. Close reiterated his Buy rating and $39 price target on Health Innovations shares.
09/12/17
ADAM
09/12/17
NO CHANGE
ADAM
Buy
Health Insurance Innovations regulatory items will get resolved, says Canaccord
Canaccord analyst Richard Close believes Health Insurance Innovations' outstanding regulatory issues will be resolved without a meaningful impact on the business, but said it could take time and remain an overhang until this is settled. Close maintains a Buy rating and said the next likely catalysts for shares would be a resolution to the Florida third-party administrator license application situation.
CCUR CCUR Holdings
$5.80

-0.03 (-0.51%)

SCHW Charles Schwab
$44.73

(0.00%)

10/06/17
RAJA
10/06/17
NO CHANGE
RAJA
Raymond James says buy Ameritrade and E-Trade on short-term weakness
Renewed concerns regarding the ability of online brokers to capture payment for order flow are not justified, Raymond James analyst Patrick O'Shaughnessy tells investors in an intraday research note. The Treasury Department's recently released report includes language that suggests downside risks for the brokers, but the topic itself is nothing new, nor are the proposed remedies, O'Shaughnessy argues. He points out that online brokerage firms are generally on board with these reforms. Further, the analyst believes the Massachusetts investigation into retail broker order routing decisions isn't likely to go anywhere. O'Shaughnessy recommends taking advantage of any short-term weakness in TD Ameritrade (AMTD) and E-Trade (ETFC). He has Outperform ratings on Ameritrade and E-Trade and a Market Perform rating on Charles Schwab (SCHW).
09/08/17
LEHM
09/08/17
INITIATION
Target $48
LEHM
Overweight
Charles Schwab initiated with an Overweight at Barclays
Barclays analyst Jeremy Campbell started Charles Schwab with an Overweight rating and $48 price target. The analyst initiated U.S. Brokers, Asset Managers & Exchanges with a Neutral industry view.
07/13/17
07/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HP Inc. (HPQ), 3D Systems (DDD), and Stratasys (SSYS) were initiated with a Neutral at Susquehanna. 2. Danaher (DHR) initiated with a Market Perform at Wells Fargo. 3. E-Trade (ETFC) and TD Ameritrade (AMTD) were initiated with a Buy at Rosenblatt, while Charles Schwab (SCHW) was initiated with a Neutral. 4. C&J Energy Services (CJ) initiated with a Buy at Jefferies. 5. BIO-key (BKYI) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
NOMU
07/24/17
DOWNGRADE
NOMU
Neutral
Charles Schwab downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Steven Chubak downgraded Charles Schwab to Neutral citing year-to-date share appreciation and high consensus forecasts. The analsyt views risk/reward as more balanced and sees downside risk to 2018 Street estimates given high NII estimates.
CXRX Concordia
$1.14

-0.02 (-1.72%)

11/08/16
RBCM
11/08/16
DOWNGRADE
RBCM
Sector Perform
Concordia downgraded on risks, uncertainty at RBC Capital
As noted earlier, RBC Capital downgraded Concordia to Sector Perform from Outperform. Analyst Douglas Miehm says that the company's outlook continues to become more uncertain, as he notes that it has suspended its guidance. Additionally, the company is being hurt by pricing pressure and an ongoing CMA probe, according to the analyst. Target to $2.50 from $10.
03/15/17
TDSI
03/15/17
NO CHANGE
Target $0.75
TDSI
Reduce
Concordia price target lowered to 75c from $1 at TD Securities
TD Securities analyst Lennox Gibbs cut his price target on Concordia to 75c and kept a Reduce rating on the stock, saying he does not expect the strategic shift signaled by its CEO to result in material improvement to results in the near-term.
12/07/16
RBCM
12/07/16
DOWNGRADE
RBCM
Underperform
Concordia downgraded to Underperform from Sector Perform at RBC Capital
02/08/17
TDSI
02/08/17
DOWNGRADE
Target $1
TDSI
Reduce
Concordia downgraded to Reduce from Hold at TD Securities
TD Securities analyst Lennox Gibbs downgraded Concordia to Reduce and lowered its price target to $1.00 from $2.50 due to deteriorating U.S. operations, diminished UK growth potential, and valuation.
ITUS ITUS
$3.19

-0.22 (-6.45%)

TODAY'S FREE FLY STORIES

TWTR

Twitter

$44.70

0.45 (1.02%)

06:15
07/18/18
07/18
06:15
07/18/18
06:15
Downgrade
Twitter rating change  »

Twitter downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

VSTM

Verastem

$8.10

-0.14 (-1.70%)

06:15
07/18/18
07/18
06:15
07/18/18
06:15
Conference/Events
Verastem management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Oct

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

, GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

06:14
07/18/18
07/18
06:14
07/18/18
06:14
Periodicals
Nest CEO removed as unit brought under Google Home team, CNet reports »

Google has removed Marwan…

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

OPTN

Optinose

$26.61

(0.00%)

06:13
07/18/18
07/18
06:13
07/18/18
06:13
Recommendations
Optinose analyst commentary  »

Optinose price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVT

Ingevity

$90.74

2.91 (3.31%)

06:12
07/18/18
07/18
06:12
07/18/18
06:12
Recommendations
Ingevity analyst commentary  »

Ingevity price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDW

CDW

$86.23

1.31 (1.54%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Upgrade
CDW rating change  »

CDW upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$11.87

-0.275 (-2.27%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Periodicals
Former Deutsche Bank exec denies index rigging in Paschi case, Bloomberg says »

Former Deutsche Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTXB

LegacyTexas Financial

$39.01

-0.04 (-0.10%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Upgrade
LegacyTexas Financial rating change  »

LegacyTexas upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

MLNX

Mellanox

$84.85

0.9 (1.07%)

06:10
07/18/18
07/18
06:10
07/18/18
06:10
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$356.95

0.94 (0.26%)

06:09
07/18/18
07/18
06:09
07/18/18
06:09
Hot Stocks
Boeing announces agreements with ANTONOV, IWG and Cargolux »

Boeing, through its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CPWR

Compuware

$0.00

(0.00%)

06:08
07/18/18
07/18
06:08
07/18/18
06:08
Hot Stocks
Compuware acquires XaTester and partners with Parasoft »

Compuware announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$25.39

-0.31 (-1.21%)

06:06
07/18/18
07/18
06:06
07/18/18
06:06
Upgrade
Sunoco rating change  »

Sunoco upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$91.84

1.15 (1.27%)

06:06
07/18/18
07/18
06:06
07/18/18
06:06
Upgrade
Comerica rating change  »

Comerica upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$77.25

0.045 (0.06%)

06:05
07/18/18
07/18
06:05
07/18/18
06:05
Hot Stocks
Target says one-day sale generates biggest online shopping day of 2018 »

Hot offers drove the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$33.52

-0.25 (-0.74%)

06:04
07/18/18
07/18
06:04
07/18/18
06:04
Upgrade
MPLX rating change  »

MPLX upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

WMB

Williams

$26.97

-0.28 (-1.03%)

, OKE

Oneok

$70.30

0.29 (0.41%)

06:03
07/18/18
07/18
06:03
07/18/18
06:03
Recommendations
Williams, Oneok analyst commentary  »

Jefferies replaces Oneok…

WMB

Williams

$26.97

-0.28 (-1.03%)

OKE

Oneok

$70.30

0.29 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GEMP

Gemphire Therapeutics

$7.78

0.525 (7.24%)

06:03
07/18/18
07/18
06:03
07/18/18
06:03
Conference/Events
Gemphire Therapeutics management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

OKE

Oneok

$70.30

0.29 (0.41%)

06:01
07/18/18
07/18
06:01
07/18/18
06:01
Downgrade
Oneok rating change  »

Oneok downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

AMD

AMD

$16.87

0.29 (1.75%)

, NVDA

Nvidia

$253.69

5.48 (2.21%)

06:00
07/18/18
07/18
06:00
07/18/18
06:00
Periodicals
AMD, NVDIA, consortium announce VirtualLink USB-C alt mode, AnandTech says »

A consortium backed by…

AMD

AMD

$16.87

0.29 (1.75%)

NVDA

Nvidia

$253.69

5.48 (2.21%)

MSFT

Microsoft

$106.00

1.09 (1.04%)

FB

Facebook

$209.99

2.66 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

  • 18

    Sep

FHN

First Horizon

$17.18

-0.715 (-4.00%)

05:59
07/18/18
07/18
05:59
07/18/18
05:59
Downgrade
First Horizon rating change  »

First Horizon downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPI

Farmland Partners

$6.28

0.185 (3.04%)

05:59
07/18/18
07/18
05:59
07/18/18
05:59
Upgrade
Farmland Partners rating change  »

Farmland Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMP

Magellan Midstream

$67.45

-0.31 (-0.46%)

05:59
07/18/18
07/18
05:59
07/18/18
05:59
Downgrade
Magellan Midstream rating change  »

Magellan Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

IRWD

Ironwood

$21.08

0.27 (1.30%)

05:58
07/18/18
07/18
05:58
07/18/18
05:58
Downgrade
Ironwood rating change  »

Ironwood downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMO

Bank of Montreal

$78.54

-0.26 (-0.33%)

05:58
07/18/18
07/18
05:58
07/18/18
05:58
Upgrade
Bank of Montreal rating change  »

Bank of Montreal upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.42

1.04 (0.37%)

05:57
07/18/18
07/18
05:57
07/18/18
05:57
General news
Trump says 'big results will come' from meeting with Putin »

President Donald Trump…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.42

1.04 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.